← Back to Clinical Trials
Recruiting NCT06810596

NCT06810596 Comparing Efficacy Between Two Protocols of Intravenous Insulin Infusion for Diabetic Adults in ICU

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06810596
Status Recruiting
Phase
Sponsor Suez Canal University
Condition Glycemic Control
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2024-12-15
Primary Completion 2025-03-01

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Insulin infusion protocol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2024-12-15 with a primary completion date of 2025-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of clinical trial is to improve the adequacy of blood sugar control in diabetic critically ill adult patients who admitted to the intensive care unit(ICU) in Suez Canal University (SCU) hospitals by comparing glycemic control efficacy between the NHS in the UK and suggested SCU Protocols of Intravenous Insulin Infusion. The main questions it aims to answer are: Is SCU protocol of Intravenous Insulin Infusion more effective than NHS protocol in achieving blood glucose control targets in critically ill adult patients? Researchers will compare glycemic control efficacy between the NHS in UK and suggested SCU Protocols of Intravenous Insulin Infusion for critically ill Adults in ICU to determine the best protocol in achieving good blood glucose control in diabetic critically ill adult patients in SCU Hospitals.

Eligibility Criteria

Inclusion Criteria: * Patients who admitted to the hospital with a potentially life-threatening condition (Critically ill patients) with HbA1C \>6.0. Exclusion Criteria: * DKA patients. * Pregnant or breast-feeding patients. * Hyperosmolar Non-Ketotic Coma.

Contact & Investigator

Central Contact

Aiman A. Al-Touny, MD

✉ Aimantouny@med.suez.edu.eg

📞 +201008185785

Frequently Asked Questions

Who can join the NCT06810596 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Glycemic Control. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06810596 currently recruiting?

Yes, NCT06810596 is actively recruiting participants. Contact the research team at Aimantouny@med.suez.edu.eg for enrollment information.

Where is the NCT06810596 trial being conducted?

This trial is being conducted at Ismailia, Egypt.

Who is sponsoring the NCT06810596 clinical trial?

NCT06810596 is sponsored by Suez Canal University. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology